drugset / Trial / NCT02690350
An Open Study Assessing the Safety and Tolerability of U3-1784
Non-randomizedSequentialOpen-labelTreatment
Summary
The main objectives of the trial are: * To evaluate the safety and tolerability of U3-1784 in patients with advanced solid tumours * To determine the maximum tolerated dose (MTD) and or establish the safety and tolerability of the maximum administered dose (MAD) of U3-1784
Timeline
- Start
- 2016-02-29
- Primary completion
- 2017-02-28
- Completion
- 2017-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | U3-1784 | Unknown | 2.5 mg/kg | Intravenous |
| Subject | U3-1784 | Unknown | 3.75 mg/kg | Intravenous |
| Subject | U3-1784 | Unknown | 5.6 mg/kg | Intravenous |
| Background | Cholestyramine | Other / unclassified | — | — |